A Phase II study to investigate lung function with 2 different doses of inhaled glycopyrronium taken with BFF compared to BFF in participants of 4 to less than 12 years of age with asthma

Trial Identifier: D5982C00015
Sponsor: AstraZeneca
Start Date: April 2026
Primary Completion Date: May 2029
Study Completion Date: May 2029
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AR Buenos Aires, AR, C1122
AR CABA, AR, 1426
AR Florencio Varela, AR, 1888
AR La Plata, AR, B1900AXI
AR Lanus Este, AR, B1824KAJ
AR Lobos, AR, 7240
AR Mar del Plata, AR, B7600
AR Mendoza, AR, M5500
AR Mendoza, AR, 5500
AR Rosario, AR, S2000CVD
AR Rosario, AR, 2000
AR Santa Fe, AR, 3000
CZ Brno, CZ, 65691
CZ Praha, CZ, 15006
HU Debrecen, HU, 4032
HU Orosháza, HU, 5900
HU Szeged, HU, 6720
HU Szekesfehervar, HU, 8000
HU Szigetvár, HU, 7900
MX Apodaca, MX, 64620
MX Guadalajara, MX, 44130
MX San Juan, MX, 00909
PL Łódź, PL, 90-329
PL Tarnów, PL, 33-100
RS Belgrade, RS, 11000
RS Belgrade, RS, 11040
RS Belgrade, RS, 11070
RS Novi Sad, RS, 21000
US, CA Bakersfield, CA, US, 93301
US, CA Long Beach, CA, US, 90806
US, CA San Diego, CA, US, 92123
US, FL Miami, FL, US, 33125
US, FL Pembroke Pines, FL, US, 33026
US, KY Owensboro, KY, US, 42301
US, LA Lafayette, LA, US, 70508
US, MA Boston, MA, US, 02114
US, MO Columbia, MO, US, 65203
US, OH Cincinnati, OH, US, 45229
US, OK Oklahoma City, OK, US, 73120